Rise and shine, folks, another busy day is on the way. Despite the mounting workload, this morning is getting off to a reasonably good start, thanks to a warm and shiny sun enveloping the Pharmalot campus. Moreover, our short people have successfully departed for their respective destinations and the official mascots have quietly settled down. All of which means the time has come to get cracking. On that note, here are some items of interest. We hope your day is productive and do keep in touch …

GlaxoSmithKline (GSK) agreed to pay Novartis (NVS) $13 billion for its 36.5 percent stake in their consumer health care joint venture, moving to consolidate the unit just three years after GSK and Novartis teamed up, the Wall Street Journal reports. The deal is the first significant strategic move for the newly installed executives running both companies and follows transactions a few years ago between the drug makers in which Glaxo beefed up consumer health and vaccines, while Novartis bought the Glaxo cancer drugs business.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy